A Beta-only IL-2 ImmunoTherapY (ABILITY) Study

Conditions:   Advanced Solid Tumor;   Unresectable Solid Tumor;   Melanoma;   Renal Cell Carcinoma;   Sarcoma;   Triple Negative Breast Cancer;   Pancreatic Ductal Adenocarcinoma;   Non-Small Cell Lung Cancer Squamous;   Non-Small Cell Lung Cancer Non-squamous;   Colorectal Cancer ;   Gastric Cancer;   Biliary Tract Cancer;   Gallbladder Cancer;   Cholangiocarcinoma;   Uterine Cancer;   Ovarian Cancer;   Cervical Cancer;   Basal Cell Carcinoma;   Bladder Cancer;   Merkel Cell Carcinoma;   Squamous Cell Carcinoma of Head and Neck;   Cutaneous Squ amous Cell Carcinoma Interventions:   Drug: MDNA11 Monotherapy;   Drug: MDNA11 in combination with checkpoint inhibitor Sponsor:   Medicenna Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials